Next Science Limited (NXSCF PINK) stock market data APIs
$0.0418
0(0%)
as of July 3, 2025
Try our APIs with
free plan!
Next Science Limited Financial Data Overview
Price chart is built with
Anychart
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Prev. Close
0.0418
Open
0.0418
High
0.0418
Low
0.0418
52 wk Range
0.005-0.197
Market Cap
25 963 K
Shares Outstanding
292 M
Revenue
22 816 K
EPS
-0.0107
Beta
1.313
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Next Science Limited data using free add-ons & libraries
Get Next Science Limited Fundamental Data
Next Science Limited Fundamental data includes:
- Net Revenue: 22 816 K
- EBITDA: -9 741 499
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Next Science Limited News
New
Investors in Next Science (ASX:NXS) have unfortunately lost 78% over the last three years
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of Next Science Limited (ASX:N...
New Study Finds XPERIENCE™ No Rinse Solution Has Persistent Efficacy Against Both Planktonic Bacteria and Bacterial Biofilms
Highlights In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log reductions in planktonic (free-floating) bacteria and 4-log to 8-log reductions in biofilm bacteria (colonies of bacteria) XPER...
What Is The Ownership Structure Like For Next Science Limited (ASX:NXS)?
Every investor in Next Science Limited (ASX:NXS) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to h...
Companies Like Next Science (ASX:NXS) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com l...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
